Krebs Biochemicals and Industries (KREBSBIO)₹59.62+3.69%Pharmaceuticals
Krebs Biochemicals and Industries is compared with the 10 closest in size in Pharmaceuticals (229 companies in the industry). It has a ROCE of −15.0% against a peer median of 11.1%, and latest-quarter sales growth of 27.4% against a peer median of 25.3%. By market cap it is #6 of 11 in this set.
As of · Peer set: 10 closest in size in Pharmaceuticals
| Company | M-cap (₹ Cr) | P/E | ROCE % | ROE % | Debt / equity | Div. yield % | Sales (₹ Cr) | Net profit (₹ Cr) | Qtr sales growth % | Qtr profit growth % | Compare |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Par Drugs and Chemicals | 139 | 9.6 | 17.0 | 12.4 | 0.00 | 0.0 | 104 | 13 | 20.2 | 41.6 | vs KREBSBIO |
| Speciality Medicines | 136 | 10.4 | 25.0 | 25.5 | 0.09 | 0.0 | 75 | 13 | 45.2 | 166.1 | vs KREBSBIO |
| Parnax Lab | 134 | 15.0 | 14.0 | 14.4 | 0.87 | 0.0 | 249 | 12 | 6.4 | −86.6 | vs KREBSBIO |
| Bal Pharma | 132 | 18.6 | 10.0 | 7.9 | 1.96 | 1.4 | 313 | 6 | 34.5 | 460.0 | vs KREBSBIO |
| Lactose (India) | 132 | 21.9 | 11.1 | 9.8 | 0.96 | 0.0 | 163 | 6 | 64.9 | 190.8 | vs KREBSBIO |
| Krebs Biochemicals and Industries | 129 | — | −15.0 | — | — | 0.0 | 24 | −17 | 27.4 | — | — |
| Asston Pharmaceuticals | 129 | 33.3 | 16.8 | 15.5 | 0.13 | 0.0 | 25 | 4 | 10.8 | −75.8 | vs KREBSBIO |
| BALAXI PHARMACEUTICALS | 125 | 55.3 | 3.0 | 0.6 | 0.23 | 0.0 | 270 | 1 | 14.1 | 336.7 | vs KREBSBIO |
| Parnax Lab | 125 | 14.0 | 14.1 | 14.4 | 0.87 | 0.0 | 249 | 12 | 6.4 | −86.6 | vs KREBSBIO |
| Godavari Drugs | 122 | 24.2 | 7.0 | 6.4 | 1.00 | 0.0 | 106 | 4 | 30.1 | 45.5 | vs KREBSBIO |
| Alpa Laboratories | 119 | 28.6 | 9.1 | 8.3 | 0.02 | 0.0 | 106 | 15 | 25.3 | −91.6 | vs KREBSBIO |
| Peer median | 129 | 20.2 | 11.1 | 11.1 | 0.55 | 0.0 | 106 | 6 | 25.3 | 43.5 |
Listed companies closest to Krebs Biochemicals and Industries in Pharmaceuticals include Par Drugs and Chemicals, Speciality Medicines, Parnax Lab, Bal Pharma, Lactose (India), Asston Pharmaceuticals, BALAXI PHARMACEUTICALS, Parnax Lab.
Par Drugs and Chemicals, with a market cap of ₹139 Cr.
Krebs Biochemicals and Industries' return on capital employed is −15.0%, below the peer median of 11.1%.